Stocks and Investing Stocks and Investing
Fri, November 3, 2023
Thu, November 2, 2023

Matt O"Brien Maintained (TNDM) at Buy with Decreased Target to $25 on, Nov 2nd, 2023


Published on 2024-10-28 07:18:17 - WOPRAI, Matt O'Brien
  Print publication without navigation


Matt O"Brien of Piper Sandler, Maintained "Tandem Diabetes Care, Inc." (TNDM) at Buy with Decreased Target from $40 to $25 on, Nov 2nd, 2023.

Matt has made no other calls on TNDM in the last 4 months.

There are 7 other peers that have a rating on TNDM. Out of the 7 peers that are also analyzing TNDM, 4 agree with Matt"s Rating of Hold. Following are those relevant analyst calls for the last 4 months;

Mike Kratky of "Leerink Partners" Initiated at Hold and Held Target at $21 on, Monday, October 16th, 2023
Joanne Wuensch of "Citigroup" Maintained at Hold with Decreased Target to $23 on, Monday, October 2nd, 2023
Jeff Johnson of "Baird" Maintained at Hold with Decreased Target to $32 on, Monday, August 21st, 2023
Larry Biegelsen of "Wells Fargo" Maintained at Hold with Decreased Target to $30 on, Friday, August 4th, 2023

These are the ratings of the 3 analyists that currently disagree with Matt;

Matthew Taylor of "Jefferies" Maintained at Strong Buy with Decreased Target to $45 on, Monday, October 2nd, 2023
Matt Miksic of "Barclays" Maintained at Buy with Decreased Target to $62 on, Monday, August 7th, 2023
Joshua Jennings of "TD Cowen" Maintained at Buy with Decreased Target to $34 on, Friday, August 4th, 2023

Contributing Sources